BiolineRx

What BiolineRx does

BioLineRx Ltd. is a clinical-stage biopharmaceutical company headquartered in Jerusalem, Israel, listed on NASDAQ (BLRX) and TASE. The company focuses on developing therapeutics for oncology and rare diseases, anchored by two technology platforms: CXCR4 inhibition via motixafortide and TET2 pathway activation via GLIX1. Its commercial asset, APHEXDA (motixafortide), is an FDA-approved subcutaneous CXCR4 antagonist for hematopoietic stem cell mobilization in multiple myeloma patients undergoing autologous transplantation.

The company's pipeline includes motixafortide in Phase 2b development for first-line metastatic pancreatic cancer (CheMo4METPANC trial co-supported with Regeneron and Columbia University) and Phase 1 evaluation for sickle cell disease stem cell mobilization with St. Jude and Washington University. GLIX1, a first-in-class oral small molecule restoring TET2 activity to selectively kill cancer cells, entered Phase 1/2a trials in glioblastoma in March 2026 under a joint venture with Hemispherian AS. USPTO patent protection on GLIX1 extends through 2040 across cancer types where cytidine deaminase is not over-expressed (over 90% of cancers).

BioLineRx operates an asset-light, partner-driven commercial model. APHEXDA is commercialized globally ex-Asia through an exclusive license to Ayrmid Ltd. (parent of Gamida Cell) and in Asia through Gloria Biosciences, generating royalty revenue of $480,000 in Q1 2026 (up 88% YoY). FY2025 revenue was $1.2M with a net loss of $2M. The company held $17.4M in cash as of Q1 2026, providing runway into H1 2027. Trial execution and pipeline progression are largely outsourced to academic medical centers (Columbia, NYU Langone, Northwestern, Moffitt, Washington University, St. Jude), with a lean internal team of 51-100 employees concentrated in clinical operations, regulatory affairs, and chemistry.

Name

BiolineRx

Legal name

BioLineRx Ltd.

Website

https://biolinerx.com

Company type

Public

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

BioLineRx is a Jerusalem-based clinical-stage biopharmaceutical company developing oncology and rare disease therapies, with FDA-approved APHEXDA (motixafortide) for multiple myeloma stem cell mobilization and pipeline assets GLIX1 for glioblastoma and motixafortide in pancreatic cancer.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO), Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)

Keywords

• Oncology therapeutics
• Stem cell mobilization
• Biopharmaceutical drug development
• CXCR4 antagonists
• Rare disease treatments

Headquarters

HQ city

Jerusalem

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. APHEXDA Product Sales: Revenue generated from commercialization of APHEXDA (motixafortide) for stem cell mobilization in multiple myeloma patients through licensing partner Ayrmid Ltd.
2. Royalties from APHEXDA: Q1 2026 revenue of $480,000, up 88% year-over-year, driven by increased royalties from APHEXDA commercialization with Ayrmid Ltd. and Gloria Biosciences.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

BioLineRx develops and out-licenses novel biopharmaceutical therapies for oncology and rare diseases. Its commercial product APHEXDA (motixafortide) is a CXCR4 antagonist approved by the FDA for hematopoietic stem cell mobilization in multiple myeloma patients undergoing autologous transplantation. The pipeline extends motixafortide into metastatic pancreatic cancer and sickle cell disease, and adds GLIX1, a first-in-class oral TET2 activator in Phase 1/2a for glioblastoma and other solid tumors. Revenue is generated through licensing royalties from commercialization partners Ayrmid Ltd. (US, non-solid-tumor indications) and Gloria Biosciences (Asia).

Product overview

BiolineRx is a clinical-stage biopharmaceutical company advancing an innovative pipeline of therapeutics for patients with cancer and rare diseases. The company's portfolio includes APHEXDA (motixafortide), an FDA-approved stem cell mobilization agent commercialized by partner Ayrmid Ltd., as well as motixafortide which is further being developed for pancreatic cancer (Phase 2) and sickle cell disease (Phase 1). The lead development asset is GLIX1, a first-in-class oral small molecule targeting DNA damage response via TET2 restoration, currently in Phase 1/2a clinical trials for glioblastoma. BiolineRx leverages full-spectrum drug development capabilities including chemistry, analytics, nonclinical and clinical development, and commercialization expertise.

Differentiator

Problem solved

Functional benefit

Brands

• APHEXDA: FDA-approved stem cell mobilization product (motixafortide) for multiple myeloma patients

Products and services

• APHEXDA (motixafortide) APHEXDA (motixafortide) is an FDA-approved CXCR4 antagonist administered as a subcutaneous injection for hematopoietic stem cell mobilization in multiple myeloma patients undergoing autologous transplantation. It is BioLineRx's only commercially approved product, generating royalty revenue through the licensing partner Ayrmid Ltd. (US, non-solid-tumor indications) and Gloria Biosciences (Asia). The same molecule (motixafortide) is also being developed in pipeline indications including metastatic pancreatic cancer (Phase 2b CheMo4METPANC trial) and sickle cell disease stem cell mobilization for gene therapy (Phase 1, in collaboration with Washington University and St. Jude).
• GLIX1 GLIX1 is a first-in-class oral small molecule that targets DNA damage repair by restoring TET2 activity, promoting selective cancer-cell killing while sparing normal cells. It is brain-penetrant and in Phase 1/2a clinical development for glioblastoma and other high-grade gliomas, with potential applications across approximately 90% of cancer types where cytidine deaminase is not over-expressed. The asset is being advanced through the BioLineRx-Hemispherian joint venture established in Q3 2025.

Quantifiable outcome

• 6.5 months median overall survival vs 4.7 months historical data in metastatic pancreatic cancer (COMBAT study)
• +5 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Hemispherian AScoreStrategic or Co-development Partner · 24 November 2025Collaboration agreement to develop GLIX1, a first-in-class oral small molecule targeting DNA damage response by restoring TET2 activity. A joint venture was established in Q3 2025 to advance GLIX1 clinical development for glioblastoma and other cancers. First-in-human Phase 1/2a trial initiated March 2026 at NYU Langone Health, Northwestern University, and Moffitt Cancer Center.
• Ayrmid Ltd. (Gamida Cell Ltd.)coreOEM/ Whitelabel/ Licensing Partner · 1 November 2024License agreement granting Ayrmid exclusive rights to develop and commercialize APHEXDA (motixafortide) across all indications except solid tumor indications, in all territories other than Asia. Ayrmid leads US commercialization of the approved stem cell mobilization product and the St. Jude sickle cell disease program.
• St. Jude Children's Research HospitalminorStrategic or Co-development Partner · 1 May 2024Clinical trial collaboration for multi-center Phase 1 clinical trial evaluating safety, tolerability, and feasibility of single-agent motixafortide for mobilization and collection of CD34+ hematopoietic stem cells in 12 patients aged 18+ with sickle cell disease. Through APHEXDA development agreement with Ayrmid, Gamida Cell leads this program.
• Gloria BiosciencescoreOEM/ Whitelabel/ Licensing Partner · 1 October 2023Agreement for development and commercialization of motixafortide across all indications in Asia. GloriaBio plans to lead a bridging study to support potential approval and commercialization of motixafortide in stem cell mobilization for autologous transplantation in patients with multiple myeloma in China, and a randomized Phase 2 trial in first-line pancreatic cancer with zimberelimab and chemotherapy.
• Columbia UniversitycoreStrategic or Co-development PartnerSponsor of CheMo4METPANC randomized Phase 2b clinical trial evaluating motixafortide in combination with PD-1 inhibitor cemiplimab (LIBTAYO) and standard chemotherapy vs chemotherapy alone in 108 first-line metastatic pancreatic cancer patients. Trial equally supported by BioLineRx and Regeneron.
• RegeneronminorStrategic or Co-development PartnerCo-supporter of the CheMo4METPANC randomized Phase 2b clinical trial in first-line metastatic pancreatic cancer, equally sharing development costs with BioLineRx.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/biolinerx_ltd
• LinkedInlinkedin.com/company/biolinerx
• Facebookfacebook.com/profile.php

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Subsidiaries1 record

Funding overview

Funding rounds19 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BiolineRx